Humacyte, Inc. (NASDAQ:HUMA) Short Interest Up 14.4% in September

Humacyte, Inc. (NASDAQ:HUMA) was the recipient of a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 16,030,000 shares, a growth of 14.4% from the September 15th total of 14,010,000 shares. Approximately 16.4% of the shares of the company are short sold. Based on an average daily trading volume, of 3,130,000 shares, the days-to-cover ratio is presently 5.1 days.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. BTIG Research lifted their target price on shares of Humacyte from $8.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, July 15th. Benchmark reaffirmed a “buy” rating and set a $15.00 price objective on shares of Humacyte in a research note on Thursday, October 10th. EF Hutton Acquisition Co. I raised shares of Humacyte to a “strong-buy” rating in a research note on Monday, September 9th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $13.00 price target on shares of Humacyte in a research report on Friday, September 20th. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $9.80.

Insider Transactions at Humacyte

In other news, Director Brady W. Dougan sold 252,676 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $6.71, for a total transaction of $1,695,455.96. Following the sale, the director now owns 4,306,464 shares of the company’s stock, valued at $28,896,373.44. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Humacyte news, Director Brady W. Dougan sold 252,676 shares of the stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $6.71, for a total transaction of $1,695,455.96. Following the transaction, the director now owns 4,306,464 shares in the company, valued at approximately $28,896,373.44. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Laura E. Niklason sold 157,704 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $5.42, for a total value of $854,755.68. Following the completion of the sale, the chief executive officer now directly owns 3,519,558 shares in the company, valued at approximately $19,076,004.36. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,084,153 shares of company stock worth $6,869,996 over the last quarter. 23.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of HUMA. SG Americas Securities LLC acquired a new position in Humacyte during the third quarter worth $174,000. The Manufacturers Life Insurance Company lifted its position in shares of Humacyte by 32.5% during the second quarter. The Manufacturers Life Insurance Company now owns 34,919 shares of the company’s stock worth $168,000 after purchasing an additional 8,557 shares in the last quarter. Millennium Management LLC boosted its stake in shares of Humacyte by 504.3% in the second quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock valued at $7,677,000 after purchasing an additional 1,334,641 shares during the period. Deerfield Management Company L.P. Series C acquired a new position in shares of Humacyte in the second quarter valued at approximately $1,550,000. Finally, AQR Capital Management LLC grew its holdings in shares of Humacyte by 1,018.4% in the second quarter. AQR Capital Management LLC now owns 256,342 shares of the company’s stock valued at $1,230,000 after purchasing an additional 233,422 shares in the last quarter. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Humacyte Trading Up 1.9 %

Shares of HUMA traded up $0.11 during mid-day trading on Wednesday, reaching $5.81. The stock had a trading volume of 3,740,722 shares, compared to its average volume of 2,260,759. The company has a debt-to-equity ratio of 0.61, a current ratio of 5.41 and a quick ratio of 5.41. The business’s fifty day moving average is $5.90 and its 200 day moving average is $5.88. Humacyte has a 52-week low of $1.96 and a 52-week high of $9.97. The firm has a market cap of $691.88 million, a price-to-earnings ratio of -5.81 and a beta of 1.45.

Humacyte (NASDAQ:HUMA) last posted its earnings results on Tuesday, August 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). On average, sell-side analysts predict that Humacyte will post -1.09 EPS for the current fiscal year.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.